Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2004 1
2005 1
2006 1
2010 1
2011 1
2013 2
2014 5
2015 5
2016 15
2017 16
2018 21
2019 19
2020 22
2021 41
2022 41
2023 42
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Results by year

Filters applied: . Clear all
The following term was ignored: %
The following term was not found in PubMed: 20Roke
Page 1
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD. Naidoo J, et al. J Clin Oncol. 2017 Mar;35(7):709-717. doi: 10.1200/JCO.2016.68.2005. Epub 2016 Sep 30. J Clin Oncol. 2017. PMID: 27646942 Free PMC article.
Neural-network wavefunctions.
McCardle K. McCardle K. Nat Comput Sci. 2022 May;2(5):284. doi: 10.1038/s43588-022-00258-5. Nat Comput Sci. 2022. PMID: 38177821 No abstract available.
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, Gianni L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer EP, Harbeck N. Krop IE, et al. J Clin Oncol. 2022 Feb 10;40(5):438-448. doi: 10.1200/JCO.21.00896. Epub 2021 Dec 10. J Clin Oncol. 2022. PMID: 34890214 Free PMC article. Clinical Trial.
PURPOSE: We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) treatment by replacing taxanes and trastuzumab with trastuzumab emtansine (T-DM1). METHODS: The phase III KAITLIN study …
PURPOSE: We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)-positive early breast …
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA. Pietanza MC, et al. J Clin Oncol. 2018 Aug 10;36(23):2386-2394. doi: 10.1200/JCO.2018.77.7672. Epub 2018 Jun 15. J Clin Oncol. 2018. PMID: 29906251 Free PMC article. Clinical Trial.
Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner.
Warde KM, Smith LJ, Liu L, Stubben CJ, Lohman BK, Willett PW, Ammer JL, Castaneda-Hernandez G, Imodoye SO, Zhang C, Jones KD, Converso-Baran K, Ekiz HA, Barry M, Clay MR, Kiseljak-Vassiliades K, Giordano TJ, Hammer GD, Basham KJ. Warde KM, et al. Nat Aging. 2023 Jul;3(7):846-865. doi: 10.1038/s43587-023-00420-2. Epub 2023 May 25. Nat Aging. 2023. PMID: 37231196
Application of Mendelian randomization to explore the causal role of the human gut microbiome in colorectal cancer.
Hatcher C, Richenberg G, Waterson S, Nguyen LH, Joshi AD, Carreras-Torres R, Moreno V, Chan AT, Gunter M, Lin Y, Qu C, Song M, Casey G, Figueiredo JC, Gruber SB, Hampe J, Hampel H, Jenkins MA, Keku TO, Peters U, Tangen CM, Wu AH, Hughes DA, Rühlemann MC, Raes J, Timpson NJ, Wade KH. Hatcher C, et al. Sci Rep. 2023 Apr 12;13(1):5968. doi: 10.1038/s41598-023-31840-0. Sci Rep. 2023. PMID: 37045850 Free PMC article.
Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
Martínez MT, Pérez-Fidalgo JA, Martín-Martorell P, Cejalvo JM, Pons V, Bermejo B, Martín M, Albanell J, Lluch A. Martínez MT, et al. Crit Rev Oncol Hematol. 2016 Jan;97:96-106. doi: 10.1016/j.critrevonc.2015.08.011. Epub 2015 Aug 11. Crit Rev Oncol Hematol. 2016. PMID: 26318092 Review.
The phase III randomized EMILIA and TR3RESA trials have shown that T-DM1 provides objective tumor responses and significantly improves progression free survival and overall survival in HER2-positive metastatic breast cancer patients previously treated with anti-HER2-based regimen …
The phase III randomized EMILIA and TR3RESA trials have shown that T-DM1 provides objective tumor responses and significantly improves progr …
Demystifying 'Deaths of Despair': An Interview with Medical Anthropologist Dr. Jennifer J. Carroll.
Phillips KU. Phillips KU. N C Med J. 2022 Sep-Oct;83(5):350-352. doi: 10.18043/ncm.83.5.350. N C Med J. 2022. PMID: 37158556 Free article.
Among the most influential barriers are overdose deaths and suicide rates, which are often referred to as "deaths of despair." In this interview, Managing Editor Kaitlin Ugolik Phillips talks with Jennifer J. Carroll, PhD, MPH, about the evolution of the concept and potent …
Among the most influential barriers are overdose deaths and suicide rates, which are often referred to as "deaths of despair." In this inter …
Understanding cancer drivers and passengers.
McCardle K. McCardle K. Nat Comput Sci. 2023 Mar;3(3):187-188. doi: 10.1038/s43588-023-00409-2. Nat Comput Sci. 2023. PMID: 38177877 No abstract available.
Drug discovery with limited resources.
McCardle K. McCardle K. Nat Comput Sci. 2023 Oct;3(10):815. doi: 10.1038/s43588-023-00546-8. Nat Comput Sci. 2023. PMID: 38177769 No abstract available.
211 results